Developing new treatments to hypoxia-driven disease
Prolong Pharmaceuticals is a clinical-stage company developing PP-007 (SANGUINATE®), an investigational oxygen-delivery therapy designed to reach oxygen-starved tissue. Our primary focus is Acute Ischemic Stroke, with potential applications across a range of conditions with acute and chronic hypoxia.
- Hemoglobin α/β
- Heme
- CO
- PEG
Latest news
- Apr 30, 2026FDA grants Breakthrough Therapy designation for PP-007 in A-LVO strokeThe designation covers PP-007 in Acute Ischemic Stroke due to anterior large vessel occlusion. (opens in a new tab)News
- Feb 4, 2026HEMERA-1 and the HERMES-24 score at ISC 2026Poster: using 24-hour scores to predict 90-day outcomes in HEMERA-1, toward earlier interim analysis in stroke drug trials. (opens in a new tab)Presentation
- Oct 20, 2025HEMERA-1 final results presented at World Stroke Congress 2025Phase 1/2 results presented in Barcelona. (opens in a new tab)Presentation